Related references
Note: Only part of the references are listed.Preparation of Irinotecan-Loaded Folate-Targeted Liposome for Tumor Targeting Delivery and Its Antitumor Activity
Ziqiang Zhang et al.
AAPS PHARMSCITECH (2012)
A novel method to load topotecan into liposomes driven by a transmembrane NH4EDTA gradient
Yuehui Yang et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2012)
Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy
Daniel Zucker et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Targeted Liposomal Drug Delivery to Monocytes andMacrophages
Ciara Kelly et al.
JOURNAL OF DRUG DELIVERY (2011)
Development of a highly stable and targetable nanoliposomal formulation of topotecan
Daryl C. Drummond et al.
JOURNAL OF CONTROLLED RELEASE (2010)
Bone marrow-targeted liposomal carriers: a feasibility study in nonhuman primates
Keitaro Sou et al.
NANOMEDICINE (2010)
Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice
Fatemeh Atyabi et al.
ACTA PHARMACEUTICA (2009)
Tumor-Targeted Nanomedicines: Enhanced Antitumor Efficacy In vivo of Doxorubicin-Loaded, Long-Circulating Liposomes Modified with Cancer-Specific Monoclonal Antibody
TamerA. El Bayoumil et al.
CLINICAL CANCER RESEARCH (2009)
Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors
Yoshiyuki Hattori et al.
JOURNAL OF CONTROLLED RELEASE (2009)
Chronic ethanol induces inhibition of antigen-specific CD8(+) but not CD4(+) immunodominant T cell responses following Listeria monocytogenes inoculation
Prajwal Gurung et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2009)
Radioactive liposomes
William Thomas Phillips et al.
WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY (2009)
Artificial lipids stabilized camptothecin incorporated in liposomes
Yoshie Maitani et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2008)
Lactone stability and tissue distribution of free and liposomal encapsulated 9-nitrocamptothecin in rats following intravenous injection
Jun Chen et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2008)
The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats
S. Dadashzadeh et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2008)
Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy
Kyung Hyun Min et al.
JOURNAL OF CONTROLLED RELEASE (2008)
In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin
Masato Watanabe et al.
JOURNAL OF CONTROLLED RELEASE (2008)
Doubly radiolabeled liposomes for pretargeted radioimmunotherapy
M. Mougin-Degraef et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2007)
Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles
Kaley D. Wilson et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2007)
Cationic lipid complexed camptothecin (EndoTAG®-2) improves antitumoral efficacy by tumor vascular targeting
M. E. Eichhorn et al.
CANCER BIOLOGY & THERAPY (2007)
Direct evidence of multicompartment aggregates in polyelectrolyte-charged liposome complexes
F. Bordi et al.
BIOPHYSICAL JOURNAL (2006)
Effect of phospholipid composition on characterization of liposomes containing 9-nitrocamptothecin
J Chen et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2006)
Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles
Kumi Kawano et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy
DC Drummond et al.
CANCER RESEARCH (2006)
Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability
M Watanabe et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2006)
Lipophilic drug transfer between liposomal and biological membranes: What does it mean for parenteral and oral drug delivery?
Alfred Fahr et al.
JOURNAL OF LIPOSOME RESEARCH (2006)
Liposomalization of SN-38 as active metabolite of CPT-11
Y Sadzuka et al.
JOURNAL OF CONTROLLED RELEASE (2005)
A novel non-toxic camptothecin formulation for cancer chemotherapy
M Berrada et al.
BIOMATERIALS (2005)
A phase I study of OSI-211 and cisplatin as intravenous infusions given on days 1, 2 and 3 every 3 weeks in patients with solid cancers
MJ MacKenzie et al.
ANNALS OF ONCOLOGY (2004)
Development and characterization of a novel liposome-based formulation of SN-38
JA Zhang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2004)
Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies
AD Bao et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Enhanced therapeutic efficacy formulation of SN-38 against of a novel liposome-based human tumor models in SCID mice
S Lei et al.
ANTI-CANCER DRUGS (2004)
Cytotoxic effect of different camptothecin formulations on human colon carcinoma in vitro
AM Sætern et al.
ANTI-CANCER DRUGS (2004)
Effect of composition on the stability of liposomal irinotecan prepared by a pH gradient method
TH Chou et al.
JOURNAL OF BIOSCIENCE AND BIOENGINEERING (2003)
Camptothecin delivery methods
A Hatefi et al.
PHARMACEUTICAL RESEARCH (2002)
Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation
JJ Liu et al.
ANTI-CANCER DRUGS (2002)
Accumulation of PEG-liposomes in the inflamed colon of rats: Potential for therapeutic and diagnostic targeting of inflammatory bowel diseases
VD Awasthi et al.
JOURNAL OF DRUG TARGETING (2002)
9-nitrocamptothecin liposome aerosol: Lack of subacute toxicity in dogs
BE Gilbert et al.
INHALATION TOXICOLOGY (2002)
Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin
ME Proulx et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity
D Bom et al.
JOURNAL OF CONTROLLED RELEASE (2001)
Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice
JP Desjardins et al.
ANTI-CANCER DRUGS (2001)
The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity
D Bom et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Effective prodrug liposome and conversion to active metabolite
Y Sadzuka
CURRENT DRUG METABOLISM (2000)
Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography
WJ Loos et al.
JOURNAL OF CHROMATOGRAPHY B (2000)